Nitro-benzamides useful as anti-arrhythmic agents

Abstract

A compound of formula (I): or a salt thereof, or a solvate thereof, wherein Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen; A represents a C 1-4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C 1-6 alkyl groups; R 1 represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of of the group of R 2 , R 3 and R 4 represents nitro the remaining members of the group of R 2 , R 3 and R 4 represent hydrogen; X represents a —CO—NH— moiety; and Z represents C 2-4 n-alkylene group wherein each carbon is optionally substituted 1 or 2 C 1-6 alkyl groups; a process for preparing such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

1 . A compound of formula (I):  
                   
       or a salt thereof, or a solvate thereof, characterised in that: 
 Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen;  
 A represents a C 1-4  n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C 1-6  alkyl groups;  
 R 1  represents hydrogen, alky, alkenyl or cycloalkyl;  
 one or two of of the group of R 2 , R 3  and R 4  represents nitro the remaining members of the group of R 2 , R 3  and R 4  represent hydrogen;  
 X represents a —CO—NH— moiety; and  
 Z represents C 2-4  n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C 1-6  alkyl groups.  
 
     
     
         2 . A compound according to    claim 1   , wherein Ar represents a substituted or unsubstituted phenyl group.  
     
     
         3 . A compound according to    claim 1    or    claim 2   , wherein Ar represents a phenyl group substituted with 1 or 2 alkoxy groups.  
     
     
         4 . A compound according to any one of    claims 1    to    3   , wherein R 1  represents hydrogen, C 1-6  alkyl, alkenyl or cycloalkyl.  
     
     
         5 . A compound according to any one of    claims 1    to    4   , wherein R 1  is hydrogen.  
     
     
         6 . A compound according to any one of    claims 1    to    5   , wherein one of R 2 , R 3  and R 4  represents nitro and the remaining members of the group of R 2 , R 3  and R 4  represent hydrogen.  
     
     
         7 . A compound according to    claim 6   , wherein R 2  represents 4-nitro and R 3  and R 4  each represents hydrogen.  
     
     
         8 . A compound according to any one of    claims 1    to    7   , wherein Z represents CH 2 CH 2 CH 2 .  
     
     
         9 . A compound according to    claim 1    being N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide; or a salt thereof, or a solvate thereof.  
     
     
         10 . A process for preparing a compound of formula (I) as defined in    claim 1   , or a salt thereof, or a solvate thereof, which process comprises: 
 (i) reacting a compound of formula (II):  
                 
    wherein A, Ar, R 1  and Z are as defined in relation to formula (I), with a compound of formula (III):  
                 
   wherein R 2 , R 3  and R 4  are as defined in relation to formula (I) and L 1  represents a leaving group; or    (ii) demethylating a compound of formula (VII):  
                 
   wherein A, Ar, R 2 , R 3 , R 4 , X and Z are as defined in relation to the compounds of formula (I); and thereafter, as required, converting any —NH— moiety so formed into a group NR 5  wherein R 5  represents C 2-6  alkyl, an alkenyl or a cycloalkyl group; or    (iii) reacting a compound of formula (VIII):  
                 
   wherein R 2 , R 3  R 4  X and Z are as defined in relation to formula (I) and L 3  is a leaving group, such as a halogen, with a compound of formula (IX):  
                 
   wherein A, Ar, R 1  are as defined in relation to formula (I);    and thereafter carrying out one or more of the following optional steps: 
 (i) converting a compound of formula (I) into a further compound of formula (I);  
 (ii) preparing a salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.  
   
     
     
         11 . A pharmaceutical composition comprising a compound of formula (I), as defined in    claim 1   , or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrer.  
     
     
         12 . A compound of formula (I), as defined in    claim 1   , or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.  
     
     
         13 . A compound of formula (I), as defined in    claim 1   , or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of arrhythmia.  
     
     
         14 . The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment of arrhythmia and ischaemic rhythm disorders.  
     
     
         15 . A method for the treatment and/or prophylaxis of arrhythmia and ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a human or non-human mammal in need thereof.